Seegene Inkomsten in het verleden

Verleden criteriumcontroles 1/6

De winst van Seegene is gedaald met een gemiddeld jaarlijks percentage van -13%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 7.2%. De inkomsten zijn groeide met een gemiddeld percentage van 3.8% per jaar. Het rendement op het eigen vermogen Seegene bedraagt 2.2% en de nettomarge bedraagt 6%.

Belangrijke informatie

-13.0%

Groei van de winst

-12.8%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.7%
Inkomstengroei	3.8%
Rendement op eigen vermogen	2.2%
Nettomarge	6.0%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Seegene (KOSDAQ:096530) Is Growing Earnings But Are They A Good Guide?

Feb 08

Recent updates

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Aug 10

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

Mar 07

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

May 06

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Mar 15

Declining Stock and Solid Fundamentals: Is The Market Wrong About Seegene, Inc. (KOSDAQ:096530)?

Dec 23

Can You Imagine How Elated Seegene's (KOSDAQ:096530) Shareholders Feel About Its 656% Share Price Gain?

Dec 08

I Ran A Stock Scan For Earnings Growth And Seegene (KOSDAQ:096530) Passed With Ease

Nov 24

Opbrengsten en kosten

Hoe Seegene geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

KOSDAQ:A096530 Opbrengsten, kosten en inkomsten (KRW Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	382,484	23,128	146,656	73,868
31 Mar 24	367,272	-3,461	140,927	72,659
31 Dec 23	367,375	669	138,067	72,733
30 Sep 23	389,688	-2,578	140,085	75,008
30 Jun 23	448,646	-8,971	152,705	76,267
31 Mar 23	492,159	18,719	163,661	84,725
31 Dec 22	853,561	182,139	190,845	94,738
30 Sep 22	1,140,776	343,230	232,753	97,173
30 Jun 22	1,295,241	447,057	237,633	98,026
31 Mar 22	1,470,535	537,404	247,844	90,520
31 Dec 21	1,370,833	536,559	240,955	75,539
30 Sep 21	1,402,531	559,365	226,099	63,951
30 Jun 21	1,424,097	618,128	204,153	50,622
31 Mar 21	1,395,194	633,289	179,976	37,764
31 Dec 20	1,125,216	502,281	140,581	25,948
30 Sep 20	717,254	321,437	86,608	17,948
30 Jun 20	421,777	175,809	63,587	13,483
31 Mar 20	176,245	55,324	45,545	10,359
31 Dec 19	121,953	26,672	39,611	9,647
30 Sep 19	118,445	26,676	40,292	9,542
30 Jun 19	110,402	23,176	39,446	9,352
31 Mar 19	105,861	14,304	39,306	9,341
31 Dec 18	102,265	10,098	39,736	10,277
30 Sep 18	97,975	5,951	40,585	10,514
30 Jun 18	94,684	4,972	39,811	11,671
31 Mar 18	91,979	4,684	37,272	15,094
31 Dec 17	88,920	3,693	35,626	12,603
30 Sep 17	83,092	6,568	33,747	10,834
30 Jun 17	80,817	4,644	33,302	8,407
31 Mar 17	77,285	5,672	33,674	3,396
31 Dec 16	73,694	7,123	33,826	3,434
30 Sep 16	70,519	2,827	32,612	3,206
30 Jun 16	67,973	6,367	32,737	3,001
31 Mar 16	65,903	6,289	31,602	2,708
31 Dec 15	65,137	6,774	30,665	2,630
30 Sep 15	63,834	9,204	30,282	2,569
30 Jun 15	63,538	8,620	28,934	2,426
31 Mar 15	63,807	8,412	28,535	2,538
31 Dec 14	64,411	9,141	28,416	2,812
30 Sep 14	65,029	8,021	27,817	2,976
30 Jun 14	65,141	8,067	27,008	3,070
31 Mar 14	62,595	9,414	26,392	2,994
31 Dec 13	58,993	9,573	24,456	2,803

Kwaliteitswinsten: A096530 heeft een grote eenmalige winst van ₩16.4B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: A096530 is in het verleden winstgevend geweest.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van A096530 is de afgelopen 5 jaar met 13% per jaar gedaald.

Versnelling van de groei: A096530 is het afgelopen jaar winstgevend geworden, waardoor de winstgroei moeilijk te vergelijken is met het 5-jarig gemiddelde.

Winst versus industrie: A096530 is het afgelopen jaar winstgevend geworden, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs -sector ( 6.1% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 2.2% ) van A096530 wordt als laag beschouwd.

Seegene Inkomsten in het verleden

Verleden criteriumcontroles 1/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019)

Seegene, Inc. to Report Fiscal Year 2020 Results on Feb 18, 2021

Seegene (KOSDAQ:096530) Is Growing Earnings But Are They A Good Guide?

Recent updates

Seegene, Inc.(KOSDAQ:A096530) dropped from FTSE All-World Index (USD)

Upcoming dividend of ₩200 per share

Investor sentiment deteriorates as stock falls 16%

Seegene, Inc. Develops mpox PCR Test Assays following the WHO Global Health Emergency Declaration

New minor risk - Share price stability

Seegene, Inc.'s (KOSDAQ:096530) Share Price Boosted 44% But Its Business Prospects Need A Lift Too

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share

Now 20% overvalued

Upcoming dividend of ₩200 per share

Full year 2023 earnings: EPS and revenues exceed analyst expectations

A Look At The Fair Value Of Seegene, Inc. (KOSDAQ:096530)

New minor risk - Share price stability

Now 28% overvalued after recent price rise

Upcoming dividend of ₩200 per share at 3.5% yield

Price target decreased by 8.8% to ₩25,000

New minor risk - Share price stability

Upcoming dividend of ₩200 per share at 3.7% yield

Consensus EPS estimates fall from profit to ₩18.00 loss

New minor risk - Share price stability

Investor sentiment improves as stock rises 18%

Seegene Inc. Unveils Solutions to Popularize Molecular Diagnostics At 2023 AACC

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 30,000 million worth of its shares.

Upcoming dividend of ₩200 per share at 3.7% yield

Upcoming dividend of ₩200 per share at 3.1% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 21%

Upcoming dividend of ₩400 per share

Investor sentiment deteriorated over the past week

Price target decreased to ₩38,667

Less than half of directors are independent

Seegene, Inc. (KOSDAQ:A096530) announces an Equity Buyback for KRW 50,000 million worth of its shares.

Upcoming dividend of ₩200 per share

Consensus revenue estimates fall by 24%

Now 20% undervalued

Investor sentiment improved over the past week

Seegene, Inc. to Pave Way for PCR Testing At Local Clinics with EU-Approved Multiplex Test and Fully Automated PCR Solution

Seegene Inc. Develops PCR Test to Detect Monkeypox Virus

Upcoming dividend of ₩400 per share

Now 24% undervalued after recent price drop

Price target decreased to ₩71,500

Seegene, Inc. Unveils World's First Commercialized '3 Ct' PCR Assay

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Now 21% undervalued after recent price drop

Seegene's Allplex™ RV Master Assay Receives Australian TGA Approval

Full year 2021 earnings: EPS and revenues miss analyst expectations

Seegene Inc. Unveils New Assay Optimized for On-Site Testing in 'Living with Covid-19' Era

Consensus revenue estimates increase by 13%

Consensus revenue estimates increase by 10%

Investor sentiment improved over the past week

Seegene Inc. to Launch New COVID-19 PCR Test with a Reduced Turnaround Time Optimized for Mass Testing

Seegene Inc. Announces Allplex Sars Cov-2 FluA/FluB/RSV Assay Approved Under Health Canada's Interim Order

Seegene Inc. Unveils Another Series of Diagnostic Test that Detects the Ever-Changing COVID-19 Variant Landscape

Seegene's High Multiplex Pcr Assay Capable of Detecting New Omicron Variant

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Seegene Inc. Unveils Fully Automated Molecular Testing System At the 2021 AACC

Price target decreased to ₩89,000

Consensus EPS estimates increase to ₩9,305

Seegene Introduces New SARS-CoV-2 Variants Detection Test That Can Screen Six Virus Variants Including the Delta and Delta Plus

Seegene Inc. Introduces its New Deployable Container Laboratory "Mobile Station", at the Medlab Middle East 2021

Investor sentiment improved over the past week

Price target decreased to ₩116,750

Seegene, Inc. Introduces an Exclusive Diagnostic System for Diagnosing Covid-19 Variants

Is Seegene, Inc. (KOSDAQ:096530) Trading At A 32% Discount?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS ₩19,324 (vs ₩1,026 in FY 2019)